Ciro Bellotta

Dr. Ciro Bellotta

Ospedale Antonio Cardarelli, Naples, Campania, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ERErika Renzi
Erika Renzi
VBValentina Baccolini
Valentina Baccolini
GMGiuseppe Migliara
Giuseppe Migliara
CBCiro Bellotta
Ciro Bellotta
MCMariateresa Ceparano
Mariateresa Ceparano
AMAzzurra Massimi
Azzurra Massimi
Despite the availability of effective and safe vaccines, the acceptance of COVID-19 vaccination is suboptimal. In this meta-analysis we quantified the prevalence estimates of COVID-19 vaccine acceptance with a specific focus on worldwide geographical differences. We searched PubMed, Scopus, Web of Science and PsycInfo up to April 2021 (PROSPERO ID: CRD42021235328). Generalized random-effects linear models with a logit link were used to calculate the pooled estimated rate of vaccine acceptance at both the global and regional level. A meta-regression analysis was performed to assess the association between COVID-19 vaccine acceptance and various characteristics of the studies. Overall, 71 articles yielding 128 prevalence estimates were included. The pooled prevalence of COVID-19 vaccination acceptance rate was 66% (95% CI: 61–71%). This varied by geographic area, ranging from 36% (95% CI: 18–60%) in Africa to 83% (95% CI: 82–84%) in Oceania, and there was high variability between countries (15.4% Cameroon–100% Bhutan). Meta-regression analysis showed that studies that investigated COVID-19 vaccination intentions using multiple choice/scoring gave a vaccine acceptance prevalence lower than studies with only two possible answers (yes/no) (ß: −1.02 95% CI: −1.41 to −0.63). Despite some variation in the estimates, the results showed that one in three people may refuse/delay COVID-19 vaccination.